Sha Ha is the Vice President of CMC at IGM Biosciences. She oversees drug substance and drug product development as well as analytical development in the Doylestown PA site. Before joining IGM, Sha was the director of Vaccine Process Development and Commercialization at Merck. She managed Phase 3 process characterization, tech transferring to CMOs, manufacturing facility design, and process validation for live virus vaccines. In her 15 years at Merck, Sha has worked on biologics and vaccines for Human Papillomavirus (HPV), Chikungunya, Dengue, Ebola, Cytomegalovirus (HCMV), and Streptococcus Pneumoniae. Her efforts in formulation, process and analytical have directly contributed to the filing, approval, and sustainable manufacturing of GARDASIL®9, VAXNEUVANCE®, and ERVEBO®. Prior to Merck, Sha was a research scientist in antibody discovery at Bayer HealthCare Pharmaceuticals for 6 years. Sha received her Ph.D. in Chemistry from Princeton University in 2001 and B.S. from Peking University in 1996.
Antibody Drug Discovery for Infectious Diseases
2pm – 5pm
2pm: Chair opening remarks: Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology
Presentations 2.10pm – 4pm:
Shark-derived nanobodies for diagnostic and therapeutic use
Dr Helen Dooley, Assistant Professor, University of Maryland School of Medicine
Developing high affinity, high avidity, IgM antibodies for the prevention and treatment of infectious diseases
Dr Sha Ha, VP, CMC, IGM Biosciences
Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants
Dr Shivshankar “Shankar” Sundaram, Director, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus
Dr Haoyang Li, Instructor, Center for Infectious Disease and Vaccine Research
La Jolla Institute for Immunology, LaJolla Institute
Tackling viral infections by human monoclonal antibodies
Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology
4.00-5:00pm Panel & Q&A with speakers: Overcoming hurdles in antibodies discovery and development against viral infection